Workflow
维立志博-B：LBL-034 II期试验首例患者成功用药
LEADS BIOLABS-BLEADS BIOLABS-B(HK:09887) Zhi Tong Cai Jing·2025-08-25 10:35

Core Viewpoint - The announcement from Valiant Biotech-B (09887) highlights the successful Phase I data of LBL-034 (GPRC5D/CD3 bispecific antibody) and the successful treatment of the first patient in the Phase II trial, marking a significant milestone in the clinical research of LBL-034 [1] Group 1 - Valiant Biotech-B has reported promising results from the Phase I trial of LBL-034, indicating strong potential for further development [1] - The successful treatment of the first patient in the Phase II trial establishes a solid foundation for advancing subsequent clinical trials [1]